Clinical Trial

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Study acronym: firmMIND
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2022-06-17; most recent amendment 2026-05-04.
Status change: Recruiting → Active, Not Recruiting 2025-04-09
Status change: Not Yet Recruiting → Recruiting 2022-11-07
Trial Details
NCT Number NCT05429268
Lead Sponsor Incyte Corporation
Conditions Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Enrollment 82 participants
Start Date 2022-12-23
Primary Completion 2026-03-30 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-05